Atezolizumab Inhibitor

Name: Atezolizumab Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5759547
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759547

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Atezolizumab, Inhibitor

Full Product Name

Atezolizumab

Product Synonym Names

Atezolizumab (anti-PD-L1); anti-PD-L1; MPDL3280A

Form/Format

Solid. Powder

Purity/Purification

99.1%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

145000

Solubility

<1mg/ml refers to the product slightly soluble or insoluble

CAS Number

1380723-44-3

Target & IC50

hPD-L1

Cell Research

Objective: Determine the binding of [111In]PD-L1-mAb to tumor cell lines Cells: NCI-H2444(Lung Cancer cell line), MDAMB231(Breast Cancer cell line),etc Concentrations: 1 uCi/100ul Incubation Time: 1 h Method: Incubating 1uCi of [111In]PD-L1-mAb with 1x106cells (in triplicate for each cell line) for 1h at 37 degree C. PD-L1 blocking was performed by adding a 10-fold molar equivalent excess of the non-labeled mAb. After incubation, cells were washed three times with cold PBS prior to counting on an automated gamma counter. Cell lines: NCI-H2444(Lung Cancer cell line), MDAMB231(Breast Cancer cell line),etc

Product Categories/Family for Atezolizumab, inhibitor

Apoptosis; PD-1/PD-L1

Product References and Citations for Atezolizumab, inhibitor

Inman BA, et al. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890.
Inman BA, et al. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890.
Deng R, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8(3):593-603.
Deng R, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8(3):593-603.
Zheng Y, et al. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered. 2017 Jul 4;8(4):367-373.
Zheng Y, et al. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered. 2017 Jul 4;8(4):367-373.
Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7.
Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7.

Other Notes

Small volumes of Atezolizumab, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Atezolizumab purchase

MBS5759547 is an inhibitor targeting Atezolizumab.